MA27497A1 - Compositions ophtalmiques pour le traitement de l'hypertension oculaire. - Google Patents
Compositions ophtalmiques pour le traitement de l'hypertension oculaire.Info
- Publication number
- MA27497A1 MA27497A1 MA28316A MA28316A MA27497A1 MA 27497 A1 MA27497 A1 MA 27497A1 MA 28316 A MA28316 A MA 28316A MA 28316 A MA28316 A MA 28316A MA 27497 A1 MA27497 A1 MA 27497A1
- Authority
- MA
- Morocco
- Prior art keywords
- agent
- eye
- treatment
- vagomimetic
- compounds
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010020772 Hypertension Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000324 neuroprotective effect Effects 0.000 abstract 2
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 abstract 1
- 108091005479 5-HT2 receptors Proteins 0.000 abstract 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 abstract 1
- 229920002148 Gellan gum Polymers 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 241000282414 Homo sapiens Species 0.000 abstract 1
- 208000001953 Hypotension Diseases 0.000 abstract 1
- 102000004257 Potassium Channel Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002908 adrenolytic effect Effects 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000002981 blocking agent Substances 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000004406 elevated intraocular pressure Effects 0.000 abstract 1
- 235000010492 gellan gum Nutrition 0.000 abstract 1
- 239000000216 gellan gum Substances 0.000 abstract 1
- 208000021822 hypotensive Diseases 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 108020001213 potassium channel Proteins 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 230000001392 vagomimetic effect Effects 0.000 abstract 1
- 229920001285 xanthan gum Polymers 0.000 abstract 1
- 235000010493 xanthan gum Nutrition 0.000 abstract 1
- 239000000230 xanthan gum Substances 0.000 abstract 1
- 229940082509 xanthan gum Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/65031—Five-membered rings having the nitrogen atoms in the positions 1 and 2
- C07F9/65038—Five-membered rings having the nitrogen atoms in the positions 1 and 2 condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
sous forme de solution ou suspension et contenant facultativement de la gomme xanthane ou de la gomme gellane. 11. Une composition conformément à la Revendication 9 oé un ingrédient actif appartient à la famille consistant de: agent bloquant adrénolytique-(beta), agent para-vagomimétique, agent vagomimétique, inhibiteur de l'anhydrase carbonique, agoniste EP4, une prostaglandine ou un dérivé de celle-ci, lipide hypotenseur, neuroprotecteur, et/ou un agoniste du récepteur 5-HT2 est ajouté. L'invention concerne des composés puissants de blocage du canal de potassium de formule I ou une préparation correspondante destinée au traitement de glaucome ou d'autres troubles qui débouchent sur une pression intraoculaire élevée dans l'oeil d'un patient. Cette invention a aussi trait à l'utilisation de tels composés de manière à engendrer un effet neuroprotecteur destiné à l'oeil d'espèces mammaliennes, notamment, des êtres humains
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42480802P | 2002-11-08 | 2002-11-08 | |
| US50009103P | 2003-09-04 | 2003-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27497A1 true MA27497A1 (fr) | 2005-08-01 |
Family
ID=32314559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28316A MA27497A1 (fr) | 2002-11-08 | 2005-06-07 | Compositions ophtalmiques pour le traitement de l'hypertension oculaire. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7196082B2 (fr) |
| EP (1) | EP1562909B1 (fr) |
| JP (2) | JP4456072B2 (fr) |
| KR (1) | KR20050072805A (fr) |
| AR (1) | AR041991A1 (fr) |
| AU (2) | AU2003287506B8 (fr) |
| BR (1) | BR0316040A (fr) |
| CA (1) | CA2505086C (fr) |
| CL (1) | CL2003002293A1 (fr) |
| DO (1) | DOP2003000747A (fr) |
| EC (1) | ECSP055781A (fr) |
| HR (1) | HRP20050409A2 (fr) |
| IS (1) | IS7822A (fr) |
| MA (1) | MA27497A1 (fr) |
| MX (1) | MXPA05004889A (fr) |
| NO (1) | NO20052751D0 (fr) |
| NZ (1) | NZ539593A (fr) |
| PE (1) | PE20040692A1 (fr) |
| PL (1) | PL377172A1 (fr) |
| RU (1) | RU2005117627A (fr) |
| TW (1) | TWI250873B (fr) |
| WO (2) | WO2004043932A1 (fr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040028469A (ko) | 2002-09-30 | 2004-04-03 | 엘지전자 주식회사 | 1 회 기록 가능한 광디스크의 디펙트 영역 관리방법 |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| BRPI0414102A (pt) * | 2003-09-04 | 2006-10-31 | Merck & Co Inc | composto, uso do mesmo, e, composição |
| US7563816B2 (en) * | 2004-07-20 | 2009-07-21 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| EP1647549A1 (fr) | 2004-10-14 | 2006-04-19 | Laboratoire Theramex | Indazoles, benzisoxazoles et benzisothiazoles en tant qu'agents oestrogéniques |
| WO2007089646A1 (fr) * | 2006-01-31 | 2007-08-09 | Array Biopharma Inc. | Inhibiteurs de kinase et méthodes d'utilisation |
| WO2007108968A2 (fr) * | 2006-03-13 | 2007-09-27 | Merck & Co., Inc. | Compositions ophtalmiques pour le traitement de l'hypertension oculaire |
| US8008481B2 (en) * | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| CA2742306A1 (fr) * | 2008-11-03 | 2010-05-06 | Chemocentryx, Inc. | Composes pour le traitement de l'osteoporose et de cancers |
| WO2012071369A2 (fr) | 2010-11-24 | 2012-05-31 | The Trustees Of Columbia University In The City Of New York | Antagoniste rbp4 non rétinoïde pour le traitement de la dégénérescence maculaire liée à l'âge et de la maladie de stargardt |
| US9333202B2 (en) | 2012-05-01 | 2016-05-10 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease |
| US10273243B2 (en) | 2013-03-14 | 2019-04-30 | The Trustees Of Columbia University In The City Of New York | 4-phenylpiperidines, their preparation and use |
| US9944644B2 (en) | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
| EP2968303B1 (fr) | 2013-03-14 | 2018-07-04 | The Trustees of Columbia University in the City of New York | Octahydrocyclopentapyrroles, leur préparation et leur utilisation |
| US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
| CN111393434B (zh) | 2014-04-30 | 2022-11-04 | 哥伦比亚大学董事会 | 取代的4-苯基哌啶及其制备和用途 |
| CN104211638A (zh) * | 2014-08-13 | 2014-12-17 | 李增 | 一种脂肪氨基取代的芸香碱类衍生物及其制备和作为抗阿尔兹海默症的药物中的应用 |
| WO2017123826A1 (fr) | 2016-01-14 | 2017-07-20 | Beth Israel Deaconess Medical Center, Inc. | Modulateurs de mastocytes et leurs utilisations |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2534580A1 (fr) | 1982-10-13 | 1984-04-20 | Synthelabo | Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent |
| US5151444B1 (en) | 1987-09-18 | 1999-07-06 | R Tech Ueno Ltd | Ocular hypotensive agents |
| WO1989010757A1 (fr) | 1988-05-10 | 1989-11-16 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis | Nouvelle preparation ophtalmique pour le traitement de glaucomes |
| US5296504A (en) | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
| DE68929435T2 (de) | 1988-09-06 | 2003-07-17 | Pharmacia Ab, Stockholm | Prostaglandinderivate zur Behandlung des grünen Stars oder einer okularen Hypertension |
| US5352708A (en) | 1992-09-21 | 1994-10-04 | Allergan, Inc. | Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
| US5922773A (en) | 1992-12-04 | 1999-07-13 | The Children's Medical Center Corp. | Glaucoma treatment |
| FR2701026B1 (fr) | 1993-02-02 | 1995-03-31 | Adir | Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| JP3208210B2 (ja) * | 1993-03-17 | 2001-09-10 | 旭化成株式会社 | 結晶性芳香族ポリカーボネートプレポリマーの製造方法及び芳香族ポリカーボネートの製造方法 |
| EP0724443A4 (fr) | 1993-06-08 | 1997-09-10 | Vide Pharmaceuticals | Procedes et comositions d'abaissement de la pression intra-oculaire |
| US5510383A (en) | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
| US5573758A (en) | 1995-04-28 | 1996-11-12 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
| AP2001002304A0 (en) * | 1996-05-03 | 2001-12-31 | Pfizer | Substituted indazole derivatives and related compounds |
| US5925342A (en) | 1996-11-13 | 1999-07-20 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of potassium channel blockers |
| GB2321455A (en) * | 1997-01-24 | 1998-07-29 | Norsk Hydro As | Lipophilic derivatives of biologically active compounds |
| EP1114816A4 (fr) | 1998-09-14 | 2002-09-04 | Ono Pharmaceutical Co | DERIVES E DE PHENYL-PROSTAGLANDINE A SUBSTITUTION-$g(V) ET MEDICAMENTS LES CONTENANT COMME INGREDIENT ACTIF |
| AP2002002555A0 (en) | 1999-12-22 | 2002-06-30 | Pfizer Prod Inc | EP4 Receptor selective agonists in the treatment of osteoporosis. |
| AU771130B2 (en) | 2000-01-18 | 2004-03-11 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| EP1268438A1 (fr) | 2000-03-17 | 2003-01-02 | Alcon, Inc | Derives de 6-hydroxy-indazole destines au traitement du glaucome |
| CA2401959A1 (fr) | 2000-03-17 | 2001-09-27 | Alcon, Inc. | Derives d'indazole 5-hydroxy permettant de traiter le glaucome |
| US6956036B1 (en) * | 2000-03-17 | 2005-10-18 | Alcon, Inc. | 6-hydroxy-indazole derivatives for treating glaucoma |
| WO2001072268A1 (fr) | 2000-03-31 | 2001-10-04 | Toray Industries, Inc. | Agents de régulation de la pousse du cheveu ou de sa formation |
| AU2001290250A1 (en) | 2000-09-21 | 2002-04-02 | Ono Pharmaceutical Co. Ltd. | Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient |
| EA200300379A1 (ru) | 2000-11-27 | 2003-08-28 | Пфайзер Продактс Инк. | Селективные агонисты рецептора ep4 в лечении остеопороза |
| FR2827861B1 (fr) | 2001-07-27 | 2004-04-02 | Aventis Pharma Sa | Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie |
-
2003
- 2003-10-14 US US10/684,990 patent/US7196082B2/en not_active Expired - Lifetime
- 2003-11-03 TW TW092130678A patent/TWI250873B/zh not_active IP Right Cessation
- 2003-11-04 KR KR1020057008142A patent/KR20050072805A/ko not_active Ceased
- 2003-11-04 BR BR0316040-8A patent/BR0316040A/pt not_active IP Right Cessation
- 2003-11-04 NZ NZ539593A patent/NZ539593A/en unknown
- 2003-11-04 CA CA002505086A patent/CA2505086C/fr not_active Expired - Fee Related
- 2003-11-04 MX MXPA05004889A patent/MXPA05004889A/es unknown
- 2003-11-04 AR ARP030104032A patent/AR041991A1/es not_active Application Discontinuation
- 2003-11-04 WO PCT/US2003/035078 patent/WO2004043932A1/fr not_active Ceased
- 2003-11-04 WO PCT/US2003/035080 patent/WO2004043933A1/fr not_active Ceased
- 2003-11-04 HR HR20050409A patent/HRP20050409A2/hr not_active Application Discontinuation
- 2003-11-04 AU AU2003287506A patent/AU2003287506B8/en not_active Ceased
- 2003-11-04 RU RU2005117627/04A patent/RU2005117627A/ru not_active Application Discontinuation
- 2003-11-04 JP JP2005507086A patent/JP4456072B2/ja not_active Expired - Fee Related
- 2003-11-04 PL PL377172A patent/PL377172A1/pl not_active Application Discontinuation
- 2003-11-04 AU AU2003286884A patent/AU2003286884A1/en not_active Abandoned
- 2003-11-04 EP EP03781747A patent/EP1562909B1/fr not_active Expired - Lifetime
- 2003-11-05 PE PE2003001115A patent/PE20040692A1/es not_active Application Discontinuation
- 2003-11-07 DO DO2003000747A patent/DOP2003000747A/es unknown
- 2003-11-07 CL CL200302293A patent/CL2003002293A1/es unknown
-
2005
- 2005-04-25 IS IS7822A patent/IS7822A/is unknown
- 2005-05-06 EC EC2005005781A patent/ECSP055781A/es unknown
- 2005-06-07 NO NO20052751A patent/NO20052751D0/no unknown
- 2005-06-07 MA MA28316A patent/MA27497A1/fr unknown
-
2006
- 2006-12-19 US US11/641,212 patent/US7547720B2/en not_active Expired - Lifetime
-
2009
- 2009-08-24 JP JP2009192691A patent/JP5061293B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6723748B2 (en) | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension | |
| MA27667A1 (fr) | Analogues de la prostaglandine comme antagonistes du recepteur de ep4 | |
| MA29684B1 (fr) | Composes de spiro-oxindole et utilisations associees en tant qu'agents therapeutiques | |
| MA27452A1 (fr) | Derives d'indole servant d'agonistes beta-2 | |
| EP1501530A4 (fr) | Analogues de la prostaglandine f2 alpha en combinaison avec des antimicrobiens pour le traitement du glaucome | |
| CA2807081C (fr) | Solutions de bimatoprost et de timolol sans conservateur | |
| LU91541I2 (fr) | latanoprost et ses dérivés pharmaceutiquement acceptables (XALATAN) | |
| JP2005514378A (ja) | 高眼圧症の治療方法 | |
| MA27443A1 (fr) | Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf) | |
| MA29170B1 (fr) | Derives puriniques agissant comme des agonistes du recepteur a2a | |
| MA27840A1 (fr) | Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2 | |
| US6649653B1 (en) | 15-fluoro prostaglandins as ocular hypotensives | |
| JP3846537B2 (ja) | コンタクトレンズ用装着液 | |
| RU2005117627A (ru) | Офтальмологические композиции для лечения глазной гипертензии | |
| ES2210018T3 (es) | Antagonistas de 5ht-2 para regular la presion intraocular y tratar el glaucoma. | |
| AU2002346671B2 (en) | Aminoalkyl-benzofuran-5-OL compounds for the treatment of glaucoma | |
| WO2012102355A1 (fr) | Composé bicyclique et son utilisation à des fins médicales | |
| MA27762A1 (fr) | Utilisation de derives de 10-hydroxy-10, 11-dihydrocarbamazepine pour le traitement de troubles affectifs | |
| JP2016056207A (ja) | プロスタグランジンアゴニストのプロドラッグの安定した水性組成物およびその使用方法 | |
| JP2003520245A5 (fr) | ||
| WO1995034302A3 (fr) | Procede utile pour reduire la pression intraoculaire dans l'×il mammalien a l'aide de composes chelatant le calcium | |
| MA30924B1 (fr) | Analogues de pyrazoles | |
| JP2005533055A5 (fr) | ||
| ATE289817T1 (de) | Arzneimittelzusammenstellung zur behandlung des erhöhten augeninnendrucks oder des glaukom | |
| MA27435A1 (fr) | DERIVES DE 4-(3,5-DICYANOPHENOXY) PYRAZOLE DESTINES A eTRE UTILISES COMME MODULATEURS DE TRANSCRIPTASE DANS LE TRAITEMENT D'AFFECTIONS PROVOQUEES PAR LE VIH |